TANG CAPITAL MANAGEMENT LLC
Q4 2013 13F-HR Holdings
Net value change ($000)
—
New positions
10
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| SALIX PHARMACEUTICAL | 26,982 | — |
| Mirati Therapeutics, Inc. | 15,608 | — |
| BMRN | 12,825 | — |
| ONCOGENEX PHARMACEUTICALS IN | 8,616 | — |
| MANNKIND CORP | 5,566 | — |
| ENDOCYTE INC | 4,974 | — |
| SOPHIRIS BIO INC. | 1,850 | — |
| DENDREON CORP COM | 238 | — |
| OPK | 94 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|